see this paragraph in that link you provided about MRK needing to save or expand its keytruda empire. DcVaxL combo could be the answer, imo. GO NWBO!
Many investors and analysts feel Merck has undue reliance on its blockbuster checkpoint inhibitor Keytruda, even though it’s projected to be the bestselling drug in the near future. Still, shareholders would like to see what the company has in mind to expand beyond Keytruda, and M&A could fit the ticket.
News 
Market Data 
Discover 
AI
